4//SEC Filing
Albers Jeffrey W. 4
Accession 0001193125-25-311505
CIK 0001815442other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 6:09 PM ET
Size
10.7 KB
Accession
0001193125-25-311505
Insider Transaction Report
Form 4
Albers Jeffrey W.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$14.18/sh+5,000$70,900→ 5,000 total - Sale
Common Stock
2025-12-08$89.32/sh−2,748$245,460→ 2,252 total - Sale
Common Stock
2025-12-08$90.30/sh−2,252$203,363→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-08−5,000→ 7,000 totalExercise: $14.18Exp: 2032-06-15→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $89.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $90.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001638474
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 6:09 PM ET
- Size
- 10.7 KB